The association of serum immunoglobulin E levels on outcomes of maximal medical therapy among patients of chronic rhinosinusitis
DOI:
https://doi.org/10.3329/bjo.v29i2.72285Keywords:
Chronic Rhinosinusitis, IgE, Lund-Mackay scoring, RSDI, QoLAbstract
Background: Chronis rhinosinusitis (CRS) is one of the highest prevalent diseases affecting a large population with significant impact on quality of life (QoL) and health care burden. It is almost universally accepted that before surgical therapy is considered, maximal medical therapy (MMT) should be used.Serum immunoglobulin E (IgE) level is a valuable diagnostic parameter in the severity of CRS patients. If relationship between outcomes of medical therapy with different levels of pretreatment Ig E levels can be established, then it may be use as a predictive factor to prioritize between medical treatment or surgery among CRS patients.
Objectives: This study aims to see whether the pretreatment serum immunoglobulin E (IgE)levels of patientswith Chronic rhinosinusitis (CRS) have any association on the outcomes of maximal medical therapy (MMT).
Methods: This quasi-experimental study wasconducted in the Department of Otolaryngology-Head & Neck Surgery, BSMMU, Dhaka from March 2017 to July 2019. Seventy cases of CRS were assigned into three groups based on pretreatment IgE level: normal (d”25 IU/ml), moderately raised (>25 to d”149 IU/ml), and high (e”150 IU/ ml). Outcomes were measured by evaluation of changes in Pre- and Post-MMTRhinosinusitis Disability Index (RSDI) and Lund-Mackay (LM) staging of HRCT- PNS.
Results: The pre-treatment and post-treatment mean of RSDI and LM scoring indicated a significant difference between normal and moderately raised groups. But High IgE showed no significant statistical differences between pretreatment and post treatment mean RSDI and LM scoring.
Conclusion: Patients of chronic rhinosinusitis withnormal and moderately raised pretreatment serum IgE levels were significantly responded to maximal medical therapy. Whereas patients with high level of IgE had poorimprovement with maximal medical therapy.
Bangladesh J Otorhinolaryngology 2023; 29(2): 81-88
Downloads
140
96
Downloads
Published
How to Cite
Issue
Section
License
Manuscripts submitted for publication in the Bangladesh Journal of Otorhinolaryngology must not have been previously submitted or published. Accepted papers become the permanent property of the Bangladesh Journal of Otorhinolaryngology. By submitting a manuscript, the authors(s) agree that copyrights for their articles are automatically transferred to Bangladesh Journal of Otorhinolaryngology, if and when the articles are accepted for publication.
The use, in this journal, of registered trade names, trade marks, etc. without special acknowledgement does not imply that such names, as defined by the relevant protection laws, be regarded as unprotected, and, thus, free for general use.
Authors who publish with this journal agree to the following terms:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
